AZN - AstraZeneca Projected Sales Volume

AZN (astrazeneca.com) - company brandmark

Leadership in developing targeted therapies and patent protection guarantee high margins for AstraZeneca PLC (AZN). The company relies on productive R&D research in the field of rare pathologies to ensure stable revenue growth. The company's expected trading volumes confirm business resilience, where the 99.33 mark reflects the current state. Global portfolio diversification effectively mitigates regulatory risks, providing reliable income protection.

AZN - AstraZeneca PLC Projected Sales Volume over the range 07/04/2022 - 11/13/2026

Comprehensive metric breakdowns and analytics for AstraZeneca Plc (AZN)

- stock value and consensus price forecast:
Price Chart AstraZeneca PLC|AZN - Broker Consensus Forecast
- market capitalization statistics:
Market Capitalization AstraZeneca Plc|AZN - Full Takeover Company Value
- book capitalization information:
Book Value per Share AstraZeneca|AZN - Book Capitalization|Market Value to Book Value Ratio astrazeneca.com|AZN - Company Total Asset Base
- debt and liquidity data:
Total Debt to Equity Ratio AstraZeneca PLC|AZN - Long-Term Loans to Capital Ratio|Short-Term Debt to Equity AstraZeneca AB|AZN - Aggregate Debt Obligations|Debts to Book Capitalization AstraZeneca Plc|AZN - Company Long-Term Debts|Company Current Liabilities AstraZeneca|Quick Ratio astrazeneca.com
- earnings and market ratios statistics:
AZN - Company Net Income|Expected Profit AstraZeneca PLC|AZN - Price to Earnings Multiple|Forward P/E Multiple AstraZeneca|AZN - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple AstraZeneca Plc|AZN - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) AstraZeneca|AZN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months astrazeneca.com|AZN - Earnings per share increase in current year|Net earnings per share growth forecast for next year AstraZeneca PLC
- sales volume and revenue indicators:
AZN - Company Annual Revenue|Company Projected Revenue AstraZeneca PLC|AZN - Price-to-Revenue Ratio|Forward P/S Multiple AstraZeneca Plc
Fundamental valuation:AstraZeneca PLC
Product sample of AstraZeneca AB

This indicator reflects market consensus expectations for future trading turnover, formed through the dynamics of opposing orders and quotes in the order book. By analyzing the company's planned sales volumes, investors assess the sustainability of AstraZeneca PLC (AZN) cash flows, where revenue security is underpinned by unique oncology patents and high barriers to entry that mitigate the pressure of government price regulation.

Analysis of competing companies

Company Projected Revenue Eli Lilly and Company (LLY)|abbvie.com - Company Revenue Forecast|Projected Sales Volume NVS (Novartis)|Company Sales Forecast Merck & Co.|Novo Nordisk Inc. - Projected Sales Volume|AMGN - Projected Sales Volume|Pfizer Inc. (PFE) - Company Projected Revenue|SNY - Company Future Sales|Company Future Sales Volume BMY|GSK (GSK Corp) - Company Projected Revenue Volume|Company Projected Revenue Takeda Pharmaceutical Company Limited (TAK)|TEVA (Teva Pharmaceutical Industries Ltd.) - Company Future Revenue|Projected Sales Volume RDY (Dr. Reddy's Laboratories)|Projected Sales Volume viatris.com VTRS|ROIV: Company Future Sales Volume|Company Expected Revenue ZLAB|BHC: Projected Sales Volume|Company Expected Sales Volume Cosmos Health Inc (COSM)